止血劑市場規模、佔有率、成長分析、按類型、按治療方法、按最終用戶、按地區 - 行業預測，2025 年至 2032 年

2023 年全球止血劑市場規模價值 73.8 億美元，預計將從 2024 年的 80.3 億美元成長到 2032 年的 157.7 億美元，預測期內（2025-2032 年）的複合年成長率為 8.8%。

由於出血性疾病和慢性病的發生率不斷上升，尤其是在老齡化人口中，止血劑市場預計將經歷顯著成長。全球範圍內外科手術的激增進一步增加了對先進止血藥物的需求。根據世界衛生組織統計，每年有超過125萬起道路交通事故導致嚴重出血，凸顯了對此類藥物的迫切需求。此外，機器人輔助手術等手術技術的進步也有望進一步推動市場需求。然而，手術費用高、報銷政策不利以及發展中地區對最新技術創新缺乏認知等挑戰可能會阻礙成長。解決這些障礙對於充分發揮市場的潛力至關重要。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

止血劑市場規模（按類型）

• 市場概況
• 凝血酶類止血劑
• 明膠基止血劑
• 膠原蛋白止血劑
• 氧化再生纖維素止血劑
• 纖維蛋白膠
• 其他

止血劑市場規模（按治療）

• 市場概況
• 心血管
• 一般外科
• 胃腸外科
• 神經外科
• 其他

止血劑市場規模（按最終用戶分類）

• 市場概況
• 醫院
• 手術中心
• 療養院
• 其他

止血劑市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Baxter International Inc.（USA）
• Becton, Dickinson and Company（USA）
• Medtronic plc（Ireland）
• Stryker Corporation（USA）
• Sanofi SA（France）
• CSL Limited（Australia）
• Zimmer Biomet Holdings, Inc.（USA）
• Teleflex Incorporated（USA）
• CryoLife, Inc.（USA）
• Integra LifeSciences Holdings Corporation（USA）
• Mallinckrodt Pharmaceuticals（UK）
• B. Braun Melsungen AG（Germany）
• Terumo Corporation（Japan）
• Smith & Nephew plc（UK）
• Haemonetics Corporation（USA）
• Ethicon, Inc.（USA）
• The Medicines Company（USA）
• Anika Therapeutics, Inc.（USA）

結論和建議

Global Hemostatic Agents Market size was valued at USD 7.38 billion in 2023 and is poised to grow from USD 8.03 billion in 2024 to USD 15.77 billion by 2032, growing at a CAGR of 8.8% during the forecast period (2025-2032).

The Hemostatic Agents Market is poised for significant growth due to the increasing prevalence of bleeding disorders and chronic diseases, particularly among the aging population. The surge in surgical procedures worldwide further amplifies demand for advanced hemostasis medications. According to the World Health Organization, over 1.25 million road injury incidents annually contribute to severe bleeding, highlighting a pressing need for these agents. Additionally, advancements in surgical techniques, such as robotic-assisted surgeries, will likely drive further market demand. However, challenges such as high surgical costs, unfavorable reimbursement policies, and a lack of awareness about recent technological innovations in developing regions may impede growth. Addressing these hurdles will be crucial for harnessing the market's full potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemostatic Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemostatic Agents Market Segmental Analysis

Global Hemostatic Agents Market is segmented by Type, Treatment, End User and region. Based on Type, the market is segmented into Thrombin Based Hemostats, Gelatin Based Hemostats, Collagen Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Combination Hemostats, Fibrin Sealants and Others. Based on Treatment, the market is segmented into Cardiovascular, General Surgery, Digestive Surgery, Neurosurgery and Others. Based on End User, the market is segmented into Hospitals, Surgery Centers, Nursing Homes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemostatic Agents Market

The global hemostatic agents market is primarily driven by the increasing frequency of surgical procedures worldwide, which has heightened the need for effective bleeding management during operations. As the number of surgeries rises, so does the incidence of bleeding complications, underscoring the importance of hemostatic products in clinical practice. Significant advancements in medical devices have enhanced the ability to achieve hemostasis, further propelling market growth. Recent data from the National Center for Biotechnology Information (NCBI) indicates that approximately 60-70% of transfused red blood cells are utilized in surgical settings, emphasizing the critical role these agents play in minimizing surgical risks and optimizing patient outcomes.

Restraints in the Global Hemostatic Agents Market

The Global Hemostatic Agents market faces several constraints that hinder its growth. One significant issue is the occurrence of uncontrolled bleeding, which poses a challenge in the widespread adoption of these agents. Although advancements have led to improved management of bleeding during surgeries and reduced infection risks, the high cost of these products remains a barrier to their utilization. Furthermore, specific surgical instruments may only be compatible with certain hemostatic agents, creating additional clinical limitations. Despite technological progress, these constraints continue to restrict the effective application of hemostatic agents in various medical scenarios, hampering their market potential.

Market Trends of the Global Hemostatic Agents Market

The Global Hemostatic Agents market is witnessing a significant trend driven by the escalating need to address hemorrhage, a leading cause of mortality in both military and civilian populations. With over 30% of traumatic deaths resulting from uncontrolled bleeding, the demand for effective hemostatic agents is surging, particularly in emergency and high-stress medical environments. These agents not only stabilize patients by mitigating risks associated with hypothermia, infections, and organ failure but also play a crucial role in trauma care. As awareness of their life-saving potential grows, investment in research and development is likely to further propel market expansion and innovation in hemostatic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemostatic Agents Market Size by Type & CAGR (2025-2032)

• Market Overview
• Thrombin Based Hemostats
• Gelatin Based Hemostats
• Collagen Based Hemostats
• Oxidized Regenerated Cellulose Based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

Global Hemostatic Agents Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Cardiovascular
• General Surgery
• Digestive Surgery
• Neurosurgery
• Others

Global Hemostatic Agents Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Surgery Centers
• Nursing Homes
• Others

Global Hemostatic Agents Market Size & CAGR (2025-2032)

• North America (Type, Treatment, End User)
  • US
  • Canada
• Europe (Type, Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CryoLife, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences Holdings Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Medicines Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations